Abstract
Abstract: :
Purpose: To evaluate the efficacy and safety of latanoprost 0.005% after switching from previous monotherapy. Method: In this multicenter, prospective, open label study we enrolled primary open-angle glaucoma or ocular hypertension patients switched from previous monotherapy (at least one week of treatment) to latanoprost for reasons of either: improved intraocular pressure (IOP) control, adverse event, non-compliance, cost or convenience. Patients were followed for three months. Results: In all 149 patients the average IOP after switching to latanoprost changed from 19.6 3.4 on previous therapy to 16.7 3.5 mm Hg. For those patients with uncontrolled IOP (n = 99) the average pressure after switching to latanoprost fell from 20.5 3.7 to 17.2 3.8 mm Hg. For those switched to latanoprost for non-IOP related reasons (n = 50), including an adverse event and non-compliance, the average IOP changed from 17.8 3.3 to 15.7 3.5 mm Hg. Specific medicines changed to latanoprost are listed in the table. Table (mm Hg ± SD) For patients switched to latanoprost for better pressure control 87% (n = 86) had at least ≥ 1 mm Hg further reduction in IOP. For patients switched for an ocular adverse event (non-IOP reason) (n = 31),100 % had resolution of the adverse event and without a ≥ 2 mm Hg increase in IOP. For those switched for non-compliance (n = 19) 79 % (n = 15) of patients demonstrated ≥ 1 mm Hg further reduction in IOP, possibly indicating greater compliance or efficacy with latanoprost. No patients were discontinued for an adverse event after switching to latanoprost. Conclusion: Latanoprost may be successfully switched to from a variety of other monotherapy medicines without incurring discontinuation from an adverse event and maintaining at least similar IOP control.
Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 354 clinical (human) or epidemiologic studies: prevalence/incidence • 353 clinical (human) or epidemiologic studies: outcomes/complications